{
    "clinical_study": {
        "@rank": "87416", 
        "arm_group": [
            {
                "arm_group_label": "Double sphincter group", 
                "arm_group_type": "Experimental", 
                "description": "patients from double sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months."
            }, 
            {
                "arm_group_label": "general gallbladder sphincter group", 
                "arm_group_type": "Other", 
                "description": "patients from general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months."
            }
        ], 
        "brief_summary": {
            "textblock": "We found a new Double sphincter which located in the neck of gallbladder\uff0cwe supposed it may\n      be related to control pressure of bile duct.Its formation is related to genetic factors."
        }, 
        "brief_title": "The Discovery of the Double Sphincter in Gallbladder", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Gallstone", 
        "condition_browse": {
            "mesh_term": [
                "Gallstones", 
                "Cholelithiasis", 
                "Cholecystolithiasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "To contrast the recurrence rate of gallstones between patients with gallbladder double\n      sphincter and patients with general gallbladder sphincter who underwent the treatment of\n      cholecystolithiasis by minimally invasive cholecystolithotomy with gallbladder reservation.\n      Method:Patients with gallbladder double sphincter and patients with general gallbladder\n      sphincter who underwent the treatment of cholecystolithiasis by minimally invasive\n      cholecystolithotomy with gallbladder reservation in The Affiliated Hospital of Guiyang\n      Medical College from May 2012 to December 2015. We collect these patients' bile during\n      surgery.Patients with gallbladder double sphincter as trial group, patients with general\n      gallbladder sphincter as control group.the overall follow-up period is 3 years. Then the\n      investigators statistically analyze improvement of cholecystolithiasis symptoms, thickness\n      of gall bladder wall, the gallbladder function and the rate of the recurrence of cholesterol\n      gallstone in 2 groups.we also analysis of the genetic differences from bile between two\n      groups."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - people with gallbladder double sphincter\n\n        Exclusion Criteria:\n\n        - people without gallbladder double sphincter"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01998451", 
            "org_study_id": "GYGDWK-03"
        }, 
        "intervention": {
            "arm_group_label": [
                "Double sphincter group", 
                "general gallbladder sphincter group"
            ], 
            "description": "patients from double sphincter group and general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.", 
            "intervention_name": "Tauroursodeoxycholic acid", 
            "intervention_type": "Drug", 
            "other_name": "TUCA"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Tauroursodeoxycholic acid", 
                "Taurochenodeoxycholic Acid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "double sphincter in gallbladder", 
            "recurrence rate of gallstones"
        ], 
        "lastchanged_date": "November 24, 2013", 
        "location": {
            "contact": {
                "last_name": "Chengyi Sun, M.D."
            }, 
            "facility": {
                "address": {
                    "city": "Guiyang", 
                    "country": "China", 
                    "state": "Guizhou", 
                    "zip": "550001"
                }, 
                "name": "The Discovery of the Double Sphincter in Gallbladder"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Discovery of the Double Sphincter in Gallbladder", 
        "overall_contact": {
            "email": "139724558@qq.com", 
            "last_name": "Chengyi Sun, M.D.", 
            "phone": "+86 851-6771326"
        }, 
        "overall_official": {
            "affiliation": "The Affiliated Hospital of Guiyang Medial College", 
            "last_name": "Chengyi Sun, M.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The gallbladder of some gallstone patients contain a new Anatomical structure named Double sphincter which located in the middle of gallbladder\uff0cwe supposed it may be related to the formation of gallstone and pressure of bile duct.Its formation is related to genetic factors.", 
            "measure": "The Discovery of The Double Sphincter in Gallbladder", 
            "safety_issue": "Yes", 
            "time_frame": "All the patients will be follow-up for an expected average of 3 years."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01998451"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The First Affiliated Hospital of Guangzhou Medical University", 
            "investigator_full_name": "Chengyi Sun", 
            "investigator_title": "professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "The First Affiliated Hospital of Guangzhou Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The First Affiliated Hospital of Guangzhou Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}